Immune Homeostasis in Sepsis and Septic Shock
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCharles University, Czech Republic
About this trial
Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.
Eligibility criteria
Qualifiers
sepsis/septic shock (SEPSIS-3)
age ≥18
informed consent
inclusion within first 24hrs after development/diagnosis of septic shock
Disqualifiers
disagreement of the patient or legal representative with the entry into the study
patients with primary or secondary immunodeficiency
presence of active haematological malignancy or an active non-haematological malignancy
Trial design
Treatments tested in this trial
- transcriptomics
- flow-cytometry
- cytokines
Treatment groups
200 Participants
are divided into 3 treatment groupsLocations
1Medical ICU, 1st Dept. of Internal Medicine, Teaching Hospital in Pilsen330 01, PilsenČeská Republika, Czechia
Sponsors and collaborators
Charles University, Czech Republic
Lead sponsor
Source ClinicalTrials.gov